ENDOTHELIAL PROGENITOR CELLS AND METHODS OF USE THEREOF

• US 20090148423A1
• Filed: 12/08/2008
• Published: 06/11/2009
• Est. Priority Date: 03/09/2004
• Status: Abandoned Application

• Current Assignee: Absorber AB (CareDx, Inc.)
• Original Assignee: Absorber AB (CareDx, Inc.)
• Inventors: Sumitran-Holgersson, Suchitra
• Application Number:
  US12/329,829
• Publication Number:
  US 20090148423A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/464409 Vascular endothelial growth factor receptors [VEGFR]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0645 Macrophages, e.g. Kuepfer cells in the liver; Monocytes
• CPC Class Codes: C12N 5/0692 Stem cells; Progenitor cells; Precursor cells

Abstract

Endothelial progenitor cells immunoreactive for VEGFR-2 or Tie-2, and CD45 are provided. Optionally the cell is immunoreactive with CD14. The cells are capable of differentiating in vivo into an endothelial cell or a smooth muscle cells. The cultures integrate well after transplantation into adult vasculature.

Claims

1. A method transplanting multipotent progenitor cells into a subject comprising

a. providing an in vitro cell culture comprising multipotential human CD144⁻

, CD45⁺ and Tie-2⁺ or VEGFR-2⁺ progenitor cells wherein said cells maintain multipotential capacity to differentiate in vivo into endothelial cells or smooth muscle cells; and

b. transplanting said cells in said subject.

2. The method of claim 1, where is said subject suffers from a vascular disorder.

3. A method of repopulating an injured blood vessel in a subject comprising administering to a subject a composition comprising a population of multipotential human CD144⁻

, CD45⁺ and Tie-2⁺ or VEGFR-2⁺ progenitor cells wherein said cells maintain multipotential capacity to differentiate in vivo into endothelial cells or smooth muscle cells.

4. The method of claim 3, wherein said composition is administered directly to the blood vessel.

5. The method of claim 3, wherein said composition is administered directly to an arterial bed.

6. The method of claim 3, wherein said blood vessel is a vein or an artery.

7. The method of claim 3, wherein said subject suffers from a vascular disorder.